Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
addendum, advertising, age, artificial, beneficial, beta, blocked, cartridge, chapter, chemotherapy, concept, configuration, decree, delay, delaying, dirucotide, dissolved, divested, Effient, endpoint, enroll, enrolling, factor, formal, innovation, Jackson, key, literature, mature, misuse, movement, Novapharm, opposed, outlicensing, placebo, progressed, progression, progressive, Ralph, release, released, resubmitted, secondary, sector, small, solanezumab, SPE, statistically, stent, stimulate, study, subcutaneously, subsidize, thrombotic, transparency, week
Filing tables
Filing exhibits
Related press release
LLY similar filings
Filing view
External links